dc.contributor.author | Ozdemir, Oktay | |
dc.contributor.author | Uresin, Yagiz | |
dc.contributor.author | Kizilirmak, Pinar | |
dc.contributor.author | Ongen, Zeki | |
dc.contributor.author | Tokgozoglu, Lale | |
dc.contributor.author | Avci, Burcak Kilickiran | |
dc.date.accessioned | 2021-03-05T18:30:30Z | |
dc.date.available | 2021-03-05T18:30:30Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Kizilirmak P., Uresin Y., Ozdemir O., Avci B. K. , Tokgozoglu L., Ongen Z., "Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials", TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, cilt.45, ss.49-66, 2017 | |
dc.identifier.other | av_cab032b1-65de-4546-85d9-b4f46eaa56db | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/134254 | |
dc.identifier.uri | https://doi.org/10.5543/tkda.2016.78006 | |
dc.description.abstract | Objective: Hypertension is the most prevalent modifiable risk factor for cardiovascular (CV) and cerebrovascular morbidity and mortality. This study aimed to assess the effects of renin-angiotensin-aldosterone system (RAAS) blockade on CV outcomes. | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | CARDIAC ve CARDIOVASCULAR SİSTEMLER | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Kardiyoloji | |
dc.title | Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials | |
dc.type | Makale | |
dc.relation.journal | TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY | |
dc.contributor.department | Yorum Consultancy Ltd , , | |
dc.identifier.volume | 45 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 49 | |
dc.identifier.endpage | 66 | |
dc.contributor.firstauthorID | 239373 | |